Latest Breaking News On - Jerome mertens - Page 1 : comparemela.com

Published: May 17, 2021 International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease Clene anticipates the expansion of disease indications for CNM-Au8 beyond amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis SALT LAKE CITY, May 17, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, received a Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine (NAM) to accelerate the preclinical development of CNM-Au8, a bioenergetic nanocatalyst, for treatment of neuronal aging-related deficits and Alzheimer’s disease. The Healthy Longevity Global Competition was founded in 2019

United statesSalt lake cityGwendolyn schankerJerome mertensBruce mackleRob etheringtonUs national academy of medicineLifesci advisorsClene nanomedicine incUniversity of innsbruck austriaNational academy of medicineExchange commissionUniversity of innsbruckInstitute for molecular biologyLifesci communicationsClene inc